LungBEAM : A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
Garrido, Pilar (Centro de Investigación Biomédica en Red de Cáncer)
Paz-Ares, Luis (Universidad Complutense de Madrid)
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau)
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Trigo, José Manuel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia))
Bosch-Barrera, J (Hospital Universitari de Girona Doctor Josep Trueta)
Garcίa-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña)
González-Larriba, José Luis (Hospital Universitario Clínico San Carlos (Madrid))
Sánchez-Torres, José Miguel (Hospital Universitario de la Princesa (Madrid))
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza)
Viñolas, Núria (Hospital Clínic i Provincial de Barcelona)
Camps, Carlos (Hospital General Universitario de Valencia)
Insa, Amelia (Hospital Clínico Universitario)
Juan, Óscar (Hospital Universitari i Politècnic La Fe (València))
Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià))
Paredes, Alfredo (Hospital de Donostia (Sant Sebastià, País Basc))
Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa))
López-Brea, Marta (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Palacios, José (Hospital Universitario Ramón y Cajal (Madrid))
Felip, Enriqueta (Hospital Universitari Vall d'Hebron)

Date:	2021
Abstract:	Objectives: The aim of LungBEAM was to determine the value of a novel epidermal growth factor receptor (EGFR) mutation test in blood based on BEAMing technology to predict disease progression in advanced non-small cell lung cancer (NSCLC) patients treated with first- or second-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Another goal was to monitor the dynamics of EGFR mutations, as well as to track EGFR exon 20 p. T790M (p. T790M) resistance during treatment, as critical indicators of therapeutic efficacy and patient survival. Methods: Stage IV NSCLC patients with locally confirmed EGFR-TKI sensitizing mutations (ex19del and/or L858R) in biopsy tissue who were candidates to receive first- or second-generation EGFR-TKI as first-line therapy were included. Plasma samples were obtained at baseline and every 4 weeks during treatment until a progression-free survival (PFS) event or until study completion (72-week follow-up). The mutant allele fraction (MAF) was determined for each identified mutation using BEAMing. Results: A total of 68 of the 110 (61. 8%) patients experienced a PFS event. Twenty-six patients (23. 6%) presented with an emergent p. T790M mutation in plasma at some point during follow-up, preceding radiologic progression with a median of 76 (interquartile ratio: 54-111) days. Disease progression correlated with the appearance of p. T790M in plasma with a hazard ratio (HR) of 1. 94 (95% confidence interval [CI], 1. 48-2. 54; p < 0. 001). The HR for progression in patients showing increasing plasma sensitizing mutation levels (positive MAF slope) versus patients showing either decreasing or unchanged plasma mutation levels (negative or null MAF slopes) was 3. 85 (95% CI, 2. 01-7. 36; p < 0. 001). Conclusion: Detection and quantification of EGFR mutations in circulating tumor DNA using the highly sensitive BEAMing method should greatly assist in optimizing treatment decisions for advanced NSCLC patients.
Note:	Altres ajuts: Sysmex Inostics GmbH.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	BEAMing ; EGFR mutations ; Liquid biopsy ; Non-small cell lung carcinoma
Published in:	Cancer Medicine, Vol. 10 Núm. 17 (september 2021) , p. 5878-5888, ISSN 2045-7634

DOI: 10.1002/cam4.4135
PMID: 34296539

11 p, 555.4 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles